跳至主要内容
临床试验/NCT00824824
NCT00824824已完成不适用

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Massachusetts Eye and Ear Infirmary1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
21
试验地点
1
主要终点
Presence of Retinal Vascular Dysregulation (RVD)

研究概览

简要总结

We have completed a study in which we examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with primary open angle glaucoma (POAG). This alteration in position produces changes in the local blood pressure at the entrance to the retinal vasculature. In a healthy retina, the vasculature adapts by dilating and constricting in order to maintain a steady blood flow rate. In an eye with POAG, this often does not occur. As a result, there are large fluctuations in blood flow which may produce the retinal neuronal damage associated with glaucoma.

The purpose of this study is to demonstrate that topical anti-glaucoma treatments with agents that have vasoactive as well as IOP-lowering effects can have a beneficial effect on maintaining a steady retinal blood flow rate even when there are changes in local blood pressure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 40 to 80 years
  • Untreated IOP greater than 21 mm Hg

排除标准

  • More than two IOP lowering medications
  • Exfoliation or pigment dispersion syndrome
  • Diabetic retinopathy
  • History of ocular surgery

研究组 & 干预措施

Brimonidine 0.2%-timolol 0.5% arm

Experimental

Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.

干预措施: Brimonidine 0.2%-0.5% timolol 0.5 (Drug)

Dorzolamide 2%-timolol 0.5% arm

Active Comparator

Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks

干预措施: Dorzolamide 2%-timolol 0.5% (Drug)

结局指标

主要结局

Presence of Retinal Vascular Dysregulation (RVD)

时间窗: 6 weeks post treatment

We determined whether RVD was present in the following way. The difference between the retinal blood flow measured while reclining for 30 minutes and the baseline retinal blood flow measured while seated was calculated. In a previous study, we found that among healthy subjects the change in the blood flow while reclining compared to baseline was +6.5% ± 12%. For this study, we defined the normal range of blood flow autoregulation as ± 2 standard deviations about the mean percentage change found in the control group in the initial study (6.5% ± 24.0%); that is, as -17.5% to +30.5%. Participants with a change in retinal blood flow induced by posture change outside this range were randomized to either dorzolamide-timolol fixed combination BID OU or brimonidine-timolol fixed combination BID OU for 6 weeks.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Louis Pasquale, MD

Director, Glaucoma Service Associate Director, Telemedicine

Massachusetts Eye and Ear Infirmary

研究点 (1)

Loading locations...

相似试验

Effect of Cosopt Versus Combigan on Retinal Vascular... | 临床试验